CLLS - セレクティス (Cellectis S.A.) セレクティス



symbol CLLS
会社名 Cellectis SA (セレクティス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS) used for gene excision correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field in pharmaceutical drug discovery programs in the agronomics bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States among others.   セレクティスは、フランスのゲノム工学会社。独自のコア技術を採用し、免疫腫瘍学の分野で製品を開発する。同社の製品には、B細胞悪性腫瘍などのCD19を有する細胞を標的とし殺傷することのできるT細胞製品のUCART19がある。また、製品の候補には、UCART123、UCARTCS1、UCART38などがある。   Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants.
本社所在地 8 rue de la Croix Jarry Paris 75013 FRA
代表者氏名 Andre Choulika アンドレ・チュリカ
代表者役職名 Chairman of the Board Chief Executive Officer Member of the Executive Board
電話番号 +33 1-8169-1600
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 135人
adr_tso 16101659
EBITDA EBITDA(百万ドル) -99.62027
終値(lastsale) 27.45
時価総額(marketcap) 441990539.55
時価総額 時価総額(百万ドル) 1121.578
売上高 売上高(百万ドル) 30.85860
企業価値(EV) 企業価値(EV)(百万ドル) 631.49400
当期純利益 当期純利益(百万ドル) -85.63750
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectis SA (ADR) revenues decreased 15% to $16.4M. Net loss decreased 30% to $32.4M. Revenues reflect Revenues decrease of 16% to $11.1M Other income decrease of 12% to $5.3M. Lower net loss reflects Financial expenses decrease of 74% to $3M (expense) Financial Income increase from $4.7M to $13M (income) Research and development expenses decrease of 5% to $36.4M (expense).



   Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting  2019-04-17 Business Wire
- Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma - Poster presentation to focus on improved manufacturing for allogeneic CAR T-cells Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical compa…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレクティス CLLS Cellectis S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)